Spinraza is a medication used in children (including newborns) and adults to treat spinal muscular atrophy. Treatment begins with four loading doses, followed by one maintenance dose every 4 months.

Brilinta belongs to a class of drugs called antiplatelet agents. For some conditions, it’s prescribed together with aspirin.* Brilinta comes as an oral tablet. It’s not available as a generic drug.

The Medicines and Healthcare products Regulatory Agency (MHRA) has granted marketing authorisation to Biogen for a higher-dose regimen of Spinraza (nusinersen) to treat 5q spinal muscular atrophy (SMA ...

The FDA approved a high-dose nusinersen regimen for spinal muscular atrophy, offering pharma teams key insights into dose optimization and lifecycle management. The FDA has approved a high-dose ...

The approval was anchored on data from the pivotal DEVOTE study that investigated the efficacy and safety of the High Dose Regimen of SPINRAZA in treatment-naïve and previously treated SPINRAZA ...

The FDA has approved a higher-dose regimen of Spinraza for spinal muscular atrophy, providing a new treatment option for patients. The regimen includes 50 milligram per 5 milliliter and 28 milligram ...

Spinraza (nusinersen) is a brand-name drug that’s prescribed for spinal muscular atrophy (SMA) in adults and children. Spinraza comes as a spinal injection that’s given by a healthcare professional ...